OT-202 / Ocumension Therap - LARVOL DELTA

Ocumension Therapeutics…is pleased to announce that the phase III clinical trial of OT-202 (Syk/VEGFR-2) for the treatment of dry eye disease ('DED') in the People’s Republic of China (the 'PRC') has enrolled its first patient (HKEXnews) - "The successful enrollment of the first patient marks an important milestone in the clinical development of OT-202 in the PRC, and demonstrates the Group’s commitment to advancing innovative therapies for DED patients."

Trial status • Dry Eye Disease • Ophthalmology

Phase III Study of OT202 in Treating Moderate to Severe Dry Eye (clinicaltrials.gov) - P3 | N=842 | Not yet recruiting | Sponsor: Ocumension Therapeutics (Suzhou) Co., Ltd

New P3 trial • Dry Eye Disease • Ophthalmology

Study of OT202 in Treating Moderate to Severe Dry Eye (clinicaltrials.gov) - P2 | N=213 | Completed | Sponsor: Ocumension Therapeutics (Shanghai) Co., Ltd

New P2 trial • Dry Eye Disease • Ophthalmology